Transfer learning of classification rules for biomarker discovery and verification from molecular profiling studies.

We present a novel framework for integrative biomarker discovery from related but separate data sets created in biomarker profiling studies. The framework takes prior knowledge in the form of interpretable, modular rules, and uses them during the learning of rules on a new data set. The framework consists of two methods of transfer of knowledge from source to target data: transfer of whole rules and transfer of rule structures. We evaluated the methods on three pairs of data sets: one genomic and two proteomic. We used standard measures of classification performance and three novel measures of amount of transfer. Preliminary evaluation shows that whole-rule transfer improves classification performance over using the target data alone, especially when there is more source data than target data. It also improves performance over using the union of the data sets.

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of motor neurons. We tested the hypothesis that proteomic analysis will identify protein biomarkers that provide insight into disease pathogenesis and are diagnostically useful. To identify ALS specific biomarkers, we compared the proteomic profile of cerebrospinal fluid (CSF) from ALS and control subjects using surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS). We identified 30 mass ion peaks with statistically significant (p < 0.01) differences between control and ALS subjects. Initial analysis with a rule-learning algorithm yielded biomarker panels with diagnostic predictive value as subsequently assessed using an independent set of coded test subjects. Three biomarkers were identified that are either decreased (transthyretin, cystatin C) or increased (carboxy-terminal fragment of neuroendocrine protein 7B2) in ALS CSF. We validated the SELDI-TOF-MS results for transthyretin and cystatin C by immunoblot and immunohistochemistry using commercially available antibodies. These findings identify a panel of CSF protein biomarkers for ALS.